Browse the corpus

This activity focuses on using busulfan to manage and treat allogeneic hematopoietic progenitor cell transplantation, particularly for patients with chronic myelogenous leukemia and other relevant disorders. As an antineoplastic alkylating agent, busulfan is a crucial medication for treating these conditions, which warrants a review of its indications, mechanisms of action, and contraindications. By exploring its pharmacokinetics, dosing regimens, adverse event profile, and clinical toxicology, this program equips participants with the knowledge to optimize busulfan therapy. This activity also discusses the significance of informed prescription practices and tailored dosage strategies to enhance treatment efficacy while minimizing potential adverse effects, thereby improving patient outcomes in managing chronic myelogenous leukemia and related conditions. Healthcare practitioners will gain an understanding of busulfan therapy, empowering them to deliver precise, secure, and individualized care to patients requiring allogeneic hematopoietic progenitor cell transplantation. By thoroughly examining FDA-approved and off-label uses, monitoring protocols, and pertinent drug interactions, participants will acquire the knowledge necessary to correctly administer busulfan, ultimately improving patient outcomes in treating chronic myelogenous leukemia and related disorders. Objectives: Identify the mechanism of action of busulfan. Identify the adverse effects profile of busulfan. Determine appropriate monitoring strategies for patients receiving busulfan. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from busulfan treatment. Access free multiple choice questions on this topic.

Signs and Symptoms of Toxicity When using busulfan, toxicity concerns are primarily associated with hepatic venous-occlusive disease, acute graft-versus-host disease, and chronic graft-versus-host disease. Most research indicates that maintaining the AUC between 78 to 101 mg*h/L significantly increases event-free survival for patients.[21] Management of Toxicity Treatment for hepatic venous-occlusive disease (also known as a hepatic sinusoidal occlusive syndrome) includes defibrotide, an antiplatelet agent, and an antithrombotic agent. Research has shown that 25 mg/kg/d of defibrotide IV for 21 days has effectively treated hepatic venous-occlusive disease.[22] Standard first-line therapy for both acute and chronic graft-versus-host disease is corticosteroids.[23]

Busulfan, a chemotherapeutic agent, requires a precise clinical strategy to maximize therapeutic efficacy while managing adverse effects during cancer treatment. Considering the serious adverse effects, busulfan should only be prescribed and administered by experienced oncologists and pharmacists. Chemotherapy protocols must be reviewed by a hematologist/oncologist. Pulmonologist consultation may be necessary for busulfan-induced pulmonary fibrosis.[24] These protocols also enhance the care for the many people who survive allogeneic hematopoietic progenitor cell transplantation. Some predict that by 2030, hematopoietic cell transplantation survivors will surpass half a million in the United States. There are currently patient-centered delivery models for cancer survivors, but not for patients who have survived hematopoietic cell transplantation. This area should be a focus of research in the future with the increasing number of patients who survive hematopoietic cell transplantation, and clinicians and healthcare workers should always be working together to help patients survive after undergoing chemotherapeutic treatments.[25] The interprofessional healthcare team of clinicians (MDs, DOs, PAs, NPs), oncologists, nurses, and pharmacists should coordinate the treatment of patients with busulfan effectively; monitoring and repeating essential laboratory tests is important. These tests include a complete blood count, liver function test, and pulmonary function test when an adverse effect is suspected. When a suspected adverse effect seems present in a patient, especially during allogeneic hematopoietic progenitor cell transplantation, nurses and other medical staff should relay this information to the doctor. Effective interprofessional communication is critical in this situation because the sooner the adverse effect is identified, the easier it will be for the clinician to treat the problem or terminate its use, improving patient outcomes while mitigating adverse events.